Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and autoimmune pipeline

PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018. Loss per diluted share was $2.08 for the year, compared with $2.27 one year prior. The clinical-stage biopharmaceutical company did not have revenue for either year. The company has a 135,000-square-foot manufacturing facility in…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -